Cs-131胶原片近距离放疗治疗复发胶质母细胞瘤的疗效与毒性
单中心回顾15例曾接受放疗的复发IDH野生型胶质母细胞瘤成人患者,在最大安全切除后术中植入Cs-131胶原片(处方剂量60 Gy/5 mm深)。中位随访13个月,中位总生存未达到,中位进展时间9个月,首次进展累积发生率53.3%,1例症状性3级放射性坏死,无因毒性再手术。
要点
- 术中Cs-131胶原片近距离放疗对复发GBM可行且耐受良好
- 远处失败仍常见,需整合有效全身治疗
- 严格患者选择(可手术切除、复发距放疗≥6个月)可能优化结局
核心结论
- 术中Cs-131胶原片近距离放疗治疗复发胶质母细胞瘤可行且耐受良好,但远处失败仍常见。
研究设计与样本
- 单中心回顾性研究,纳入15例既往放疗后复发、IDH野生型胶质母细胞瘤成人患者,接受最大安全切除联合术中Cs-131胶原片植入。
主要发现
- 中位随访13个月(范围1.4-21),Cs-131植入后中位总生存未达到(95%CI 6.7-NR个月)。
- Cs-131植入后中位进展时间9个月(95%CI 6.0-NR),随访期间首次进展累积发生率53.3%。
- 首次失败模式为局部2例、边缘2例、远处3例、局部合并远处1例。
- 1例出现症状性3级放射性坏死,经贝伐珠单抗改善,无患者因Cs-131毒性需再手术。
关键数值与推荐
- 处方剂量为5 mm深度处60 Gy。
- 患者中位年龄63岁(范围39-76),中位KPS 90(范围70-100),既往多数接受60 Gy/30次化放疗。
- 中位植入片数6.5片/人(范围3-13),12例(80%)首次复发植入,3例(20%)第二次复发植入,距外照射中位15个月(范围8.9-47)。
临床怎么用
- 对可手术切除、复发距既往放疗≥6个月且预期全切的复发GBM,可考虑术中Cs-131胶原片植入作为局灶剂量强化。
- 需关注远处失败,应结合有效全身治疗并严格选择患者。
局限性
- 单中心、小样本(15例)回顾性研究,随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recurrence in glioblastoma (GBM) is common, and the success of salvage strategies, including re-resection and reirradiation, is limited. Brachytherapy with Cs-131 collagen tiles enables intraoperative focal dose intensification with rapid dose fall-off and limited normal brain radiation exposure. We report the outcomes of Cs-131 collagen tile implantation at the time of resection for recurrent GBM. METHODS AND MATERIALS: We reviewed 15 adults with previously irradiated, recurrent isocitrate dehydrogenase (IDH) wild-type GBM who underwent maximal safe resection followed by intraoperative Cs-131 collagen tile implantation at a single institution. Candidates had surgically accessible, primarily enhancing recurrences ≥6 months after prior external beam radiation therapy, and were anticipated to have a gross total resection. The prescription dose was 60 Gy at a depth of 5 mm. We assessed overall survival, progression-free survival, toxicity, and patterns of failure (local ≤0.5 cm from the cavity, marginal 0.5-1 cm, and distant >1 cm) after implantation. RESULTS: Patients (median age, 63 years; range, 39-76) had good performance status (median Karnofsky Performance Status score, 90; range, 70-100) and prior chemoradiation (most to 60 Gy/30 fractions). Tiles (median, 6.5/patient; range, 3-13) were implanted at first recurrence in 12 of 15 patients (80%) and at second recurrence in 3 (20%), at a median of 15 months after external beam radiation therapy (range, 8.9-47). At 13 months median follow-up (range, 1.4-21), the median overall survival after Cs-131 implantation was not reached (NR) (95% CI, 6.7-NR months); the median time to progression after Cs-131 implantation was 9 months (95% CI, 6.0-NR); and the cumulative incidence of first progression (local or distant) after Cs-131 implantation was 53.3% over the follow-up period. The first failures were local (n = 2), marginal (n = 2), distant (n = 3), and combined local and distant (n = 1). One patient developed symptomatic grade 3 radionecrosis, which improved with bevacizumab. No patients required reoperation for Cs-131 toxicity. CONCLUSIONS: Intraoperative Cs-131 tile brachytherapy for recurrent GBM is feasible and well tolerated. Distant failures remain common. Integrating effective systemic therapy and careful patient selection may optimize outcomes.
引用
- Haisraely O, Tom MC, Perni S, et al. Cs-131 Collagen Tile Brachytherapy for Recurrent Glioblastoma: Treatment Outcomes and Toxicity. Pract Radiat Oncol. 2025. PMID: 41360286. doi:10.1016/j.prro.2025.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。